



# R&D AUSTRIA

## R&D GLOBAL

At Takeda, we work with passion and purpose, motivated by our shared goal to deliver better health and a brighter future to millions of people around the world. Our R&D efforts are focused on addressing high unmet medical needs across our core therapeutic areas of Oncology, Rare Genetics & Hematology, Neuroscience and Gastrointestinal and Inflammation. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

R&D EMPLOYEES GLOBALLY

**~5,000+**



**180+**

Active collaborations

APPROX.

**25**

New Molecular Entity Clinical Stage Assets

## R&D AUSTRIA

R&D Austria is a central player in Takeda's global R&D engine. Our R&D activities in Austria cover the entire pharmaceutical development process from the selection of a product candidate over the monitoring of clinical trials up to the market release of the product.



We are focused on addressing high unmet medical need across our core therapeutic areas



We are acknowledged experts in recombinant biologics, and process development 5.0 platforms



We enable product candidates, develop & improve manufacturing processes to support clinical trials and market approval



We provide solutions to process and product related challenges in a fast-paced, highly professional environment



We developed 10+ medicines\*



Medicines we develop are exported to 100+ countries worldwide



We are 180+ employees



We do cutting-edge research, publish in renowned journals and successfully file for patents

\* Administered after regulatory approval and/or in any stage of clinical development



Better Health, Brighter Future

## WE SEEK INNOVATION AND PARTNER TO NURTURE IT, WHEREVER IT RESIDES

We work with partners to create complementary collaborations where our global reach, scientific expertise and clinical excellence can help them bring their scientific innovation and vision to patients. Our partners include academia, start-ups, research institutes, health care providers, student & alumni networks.

“ We want to be THE recognized and well-known partner of choice when working with academia/ start-ups in the field of product development and technology innovation in Europe.”



**Dr. Manfred Rieger**  
Site Head R&D Austria

<b>OUR FOCUS</b>	<b>RECOMBINANT BIOLOGICS</b>		<b>INDUSTRY 5.0 PLATFORMS</b>		
	Large complex recombinant proteins	Development of production processes for biologics	Development of analytical methods and testing strategies	Lab of the Future: Robotics, XR, Artificial intelligence, in-silico CMC	Commercial production implementation and process validation
<b>OUR EXPERTISE</b>					
<b>OUR INTEREST</b>	<b>Analytics &amp; Device Technologies</b>	<b>Development platform &amp; delivery systems</b>	<b>Automation &amp; Robotics</b>	<b>Scientific &amp; Know-how Exchange with experts</b>	

## OUR NEW R&D AUSTRIA FACILITY

A new, state-of-the-art lab and office building in Vienna will become the main office of R&D Austria (planned opening date is 2026). This ‘Lab of the Future’ will be environmentally friendly, wheelchair accessible, and modular, meeting the needs of a modern R&D organization. It will be equipped with high-end infrastructure to develop innovative technologies using robotics, augmented reality, artificial intelligence, and simulations of processes using digital twins.



**250 EMPLOYEES**



**~ 25.000 m<sup>2</sup>**



**ENVIRONMENTALLY FRIENDLY BUILDING**

✉ [RnD.Austria@takeda.com](mailto:RnD.Austria@takeda.com)

[www.takeda.com](http://www.takeda.com)